+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Respiratory Disease Drug Development Pipeline Review, 2018

  • ID: 4714906
  • Report
  • 361 Pages
  • GBI Research
1 of 4

FEATURED COMPANIES

  • 4D Pharma PLC
  • Biogen Inc
  • Galecto Biotech AB
  • Knopp Biosciences LLC
  • OliX Pharmaceuticals Inc
  • ReveraGen BioPharma Inc
  • MORE

Asthma is a chronic disease involving the airways in the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, being overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. There are 275 products in development for this indication.

COPD is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs, leading to shortness of breath and blocked airflow to the lungs. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over time, increasing complications. The main risk factor is smoking. Exposure to chemicals and air pollution also contribute in the development of COPD. There are 187 products in development for this indication.

IPF is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. There are 136 products in development for this indication.

Molecular targets in development for chronic respiratory diseases include phosphodiesterases, adrenergic receptors, interleukins and chemokine receptors. Companies operating in this pipeline space include AstraZeneca, GlaxoSmithKline and Galapagos.

This report “Chronic Respiratory Disease Drug Development Pipeline Review, 2018”, provides an overview of the pipeline landscape for chronic respiratory diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 4D Pharma PLC
  • Biogen Inc
  • Galecto Biotech AB
  • Knopp Biosciences LLC
  • OliX Pharmaceuticals Inc
  • ReveraGen BioPharma Inc
  • MORE

1 Introduction
1.1 Chronic Respiratory Disease Report Coverage
1.2 Asthma - Overview
1.3 Chronic Obstructive Pulmonary Disease (COPD) - Overview
1.4 Idiopathic Pulmonary Fibrosis - Overview

2 Therapeutics Development
2.1 Asthma
2.2 Chronic Obstructive Pulmonary Disease (COPD)
2.3 Idiopathic Pulmonary Fibrosis

3 Therapeutics Assessment
3.1 Asthma
3.2 Chronic Obstructive Pulmonary Disease (COPD)
3.3 Idiopathic Pulmonary Fibrosis

4 Companies Involved in Therapeutics Development
4.1 Asthma
4.2 Chronic Obstructive Pulmonary Disease (COPD)
4.3 Idiopathic Pulmonary Fibrosis

5 Dormant Projects
5.1 Asthma
5.2 Chronic Obstructive Pulmonary Disease (COPD)
5.3 Idiopathic Pulmonary Fibrosis

6 Discontinued Products
6.1 Asthma
6.2 Chronic Obstructive Pulmonary Disease (COPD)
6.3 Idiopathic Pulmonary Fibrosis

7 Product Development Milestones
7.1 Asthma
7.2 Chronic Obstructive Pulmonary Disease (COPD)
7.3 Idiopathic Pulmonary Fibrosis

8 Appendix
8.1 Methodology
8.2 Coverage
8.3 Secondary Research
8.4 Primary Research
8.5 Expert Panel Validation
8.6 Contact Us
8.7 Disclaimer

List of Tables
Table 1: Number of Products under Development for Asthma
Table 2: Number of Products under Development by Companies, Asthma
Table 3: Number of Products under Development by Universities/Institutes, Asthma
Table 4: Products under Development by Companies, Asthma
Table 5: Products under Development by Universities/Institutes, Asthma
Table 6: Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD)
Table 7: Number of Products under Development by Companies, Chronic Obstructive Pulmonary Disease (COPD)
Table 8: Number of Products under Development by Universities/Institutes, Chronic Obstructive Pulmonary Disease (COPD)
Table 9: Products under Development by Companies, Chronic Obstructive Pulmonary Disease (COPD)
Table 10: Products under Development by Universities/Institutes, Chronic Obstructive Pulmonary Disease (COPD)
Table 11: Number of Products under Development for Idiopathic Pulmonary Fibrosis
Table 12: Number of Products under Development by Companies, Idiopathic Pulmonary Fibrosis
Table 13: Number of Products under Development by Universities/Institutes, Idiopathic Pulmonary Fibrosis
Table 14: Products under Development by Companies, Idiopathic Pulmonary Fibrosis
Table 15: Products under Development by Universities/Institutes, Idiopathic Pulmonary Fibrosis
Table 16: Number of Products by Stage and Target, Asthma
Table 17: Number of Products by Stage and Mechanism of Action, Asthma
Table 18: Number of Products by Stage and Route of Administration, Asthma
Table 19: Number of Products by Stage and Molecule Type, Asthma
Table 20: Number of Products by Stage and Target, Chronic Obstructive Pulmonary Disease (COPD)
Table 21: Number of Products by Stage and Mechanism of Action, Chronic Obstructive Pulmonary Disease (COPD)
Table 22: Number of Products by Stage and Route of Administration, Chronic Obstructive Pulmonary Disease (COPD)
Table 23: Number of Products by Stage and Molecule Type, Chronic Obstructive Pulmonary Disease (COPD)
Table 24: Number of Products by Stage and Target, Idiopathic Pulmonary Fibrosis
Table 25: Number of Products by Stage and Mechanism of Action, Idiopathic Pulmonary Fibrosis
Table 26: Number of Products by Stage and Route of Administration, Idiopathic Pulmonary Fibrosis
Table 27: Number of Products by Stage and Molecule Type, Idiopathic Pulmonary Fibrosis
Table 28: Asthma - Pipeline by 4D Pharma PLC
Table 29: Asthma - Pipeline by AB Science SA
Table 30: Asthma - Pipeline by AbbVie Inc
Table 31: Asthma - Pipeline by Abeome Corp
Table 32: Asthma - Pipeline by Accolade Pharmaceuticals LLC
Table 33: Asthma - Pipeline by Adamis Pharmaceuticals Corp
Table 34: Asthma - Pipeline by ALK-Abello AS
Table 35: Asthma - Pipeline by Allergan Plc
Table 36: Asthma - Pipeline by Allergopharma GmbH & Co KG
Table 37: Asthma - Pipeline by Almirall SA
Table 38: Asthma - Pipeline by Amgen Inc
Table 39: Asthma - Pipeline by Amphastar Pharmaceuticals Inc
Table 40: Asthma - Pipeline by AnaptysBio Inc
Table 41: Asthma - Pipeline by AnGes Inc
Table 42: Asthma - Pipeline by Antisense Therapeutics Ltd
Table 43: Asthma - Pipeline by Apollo Endosurgery Inc
Table 44: Asthma - Pipeline by ASIT Biotech SA
Table 45: Asthma - Pipeline by Aslan Pharmaceuticals Pte Ltd
Table 46: Asthma - Pipeline by Astellas Pharma Inc
Table 47: Asthma - Pipeline by AstraZeneca Plc
Table 48: Asthma - Pipeline by Aurigene Discovery Technologies Ltd
Table 49: Asthma - Pipeline by Biocon Ltd
Table 50: Asthma - Pipeline by BiosanaPharma BV
Table 51: Asthma - Pipeline by Biotec Pharmacon ASA
Table 52: Asthma - Pipeline by Boehringer Ingelheim GmbH
Table 53: Asthma - Pipeline by Celon Pharma SA
Table 54: Asthma - Pipeline by Chiesi Farmaceutici SpA
Table 55: Asthma - Pipeline by Crossject SA
Table 56: Asthma - Pipeline by CrystalGenomics Inc
Table 57: Asthma - Pipeline by CSL Ltd
Table 58: Asthma - Pipeline by CSPC Pharmaceutical Group Limited
Table 59: Asthma - Pipeline by Cumberland Pharmaceuticals Inc
Table 60: Asthma - Pipeline by Cynata Therapeutics Ltd

List of Figures
Figure 1: Number of Products under Development for Asthma
Figure 2: Number of Products under Development by Companies, Asthma
Figure 3: Number of Products under Development by Universities/Institutes, Asthma
Figure 4: Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD
Figure 5: Number of Products under Development by Companies, Chronic Obstructive Pulmonary Disease (COPD)
Figure 6: Number of Products under Development by Universities/Institutes, Chronic Obstructive Pulmonary Disease (COPD)
Figure 7: Number of Products under Development for Idiopathic Pulmonary Fibrosis
Figure 8: Number of Products under Development by Companies, Idiopathic Pulmonary Fibrosis
Figure 9: Number of Products under Development by Universities/Institutes, Idiopathic Pulmonary Fibrosis
Figure 10: Number of Products by Top 10 Targets, Asthma
Figure 11: Number of Products by Stage and Top 10 Targets, Asthma
Figure 12: Number of Products by Top 10 Mechanism of Actions, Asthma
Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Asthma
Figure 14: Number of Products by Top 10 Routes of Administration, Asthma
Figure 15: Number of Products by Stage and Top 10 Routes of Administration, Asthma
Figure 16: Number of Products by Top 10 Molecule Types, Asthma
Figure 17: Number of Products by Stage and Top 10 Molecule Types, Asthma
Figure 18: Number of Products by Top 10 Targets, Chronic Obstructive Pulmonary Disease (COPD)
Figure 19: Number of Products by Stage and Top 10 Targets, Chronic Obstructive Pulmonary Disease (COPD)
Figure 20: Number of Products by Top 10 Mechanism of Actions, Chronic Obstructive Pulmonary Disease (COPD)
Figure 21: Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Obstructive Pulmonary Disease (COPD)
Figure 22: Number of Products by Top 10 Routes of Administration, Chronic Obstructive Pulmonary Disease (COPD)
Figure 23: Number of Products by Stage and Top 10 Routes of Administration, Chronic Obstructive Pulmonary Disease (COPD)
Figure 24: Number of Products by Top 10 Molecule Types, Chronic Obstructive Pulmonary Disease (COPD)
Figure 25: Number of Products by Stage and Top 10 Molecule Types, Chronic Obstructive Pulmonary Disease (COPD)
Figure 26: Number of Products by Top 10 Targets, Idiopathic Pulmonary Fibrosis
Figure 27: Number of Products by Stage and Top 10 Targets, Idiopathic Pulmonary Fibrosis
Figure 28: Number of Products by Top 10 Mechanism of Actions, Idiopathic Pulmonary Fibrosis
Figure 29: Number of Products by Stage and Top 10 Mechanism of Actions, Idiopathic Pulmonary Fibrosis
Figure 30: Number of Products by Routes of Administration, Idiopathic Pulmonary Fibrosis
Figure 31: Number of Products by Stage and Routes of Administration, Idiopathic Pulmonary Fibrosis
Figure 32: Number of Products by Top 10 Molecule Types, Idiopathic Pulmonary Fibrosis
Figure 33: Number of Products by Stage and Top 10 Molecule Types, Idiopathic Pulmonary Fibrosis

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 4D Pharma PLC
  • AbbVie Inc
  • Accolade Pharmaceuticals LLC
  • Ache Laboratorios Farmaceuticos SA
  • AdAlta Ltd
  • Advanced Inhalation Therapies (AIT) Ltd
  • Aeolus Pharmaceuticals Inc
  • AlgiPharma AS
  • ALK-Abello AS
  • Allergan Plc
  • Allergopharma GmbH & Co KG
  • Allinaire Therapeutics LLC
  • Almirall SA
  • Amgen Inc
  • Amphastar Pharmaceuticals Inc
  • Amplia Therapeutics Ltd
  • AnaMar AB
  • AnaptysBio Inc
  • AnGes Inc
  • Angiocrine Bioscience Inc
  • Antisense Therapeutics Ltd
  • Apollo Endosurgery Inc
  • Aridis Pharmaceuticals Inc
  • Asahi Kasei Corp
  • ASIT Biotech SA
  • Aslan Pharmaceuticals Pte Ltd
  • Aurigene Discovery Technologies Ltd
  • AusBio Ltd
  • BerGenBio ASA
  • Biocon Ltd
  • Biogen Inc
  • BiosanaPharma BV
  • BioStem Technologies Inc
  • Biotec Pharmacon ASA
  • BreStem Therapeutics Inc
  • Bristol-Myers Squibb Co
  • C4X Discovery Holdings PLC
  • Celdara Medical LLC
  • Celgene Corp
  • Certa Therapeutics Pty Ltd
  • China Resources Pharmaceutical Group Ltd
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Cipla Ltd
  • Circassia Pharmaceuticals Plc
  • Compugen Ltd
  • Crossject SA
  • CrystalGenomics Inc
  • CSPC Pharmaceutical Group Limited
  • Cumberland Pharmaceuticals Inc
  • Daewoong Pharmaceutical Co Ltd
  • Denceptor Therapeutics Ltd
  • Denovo Biopharma LLC
  • Diffusion Pharmaceuticals Inc
  • Domainex Ltd
  • Energenesis Biomedical Co Ltd
  • Errant Gene Therapeutics LLC
  • Evaxion Biotech ApS
  • FibroGen Inc
  • FibroStatin SL
  • FLX Bio Inc
  • Fountain Biopharma Inc
  • Galecto Biotech AB
  • Genentech Inc
  • GeneScience Pharmaceuticals Co Ltd
  • GenKyoTex SA
  • Gilead Sciences Inc
  • Global Blood Therapeutics Inc
  • Gossamer Bio Inc
  • Grifols SA
  • Guangdong Zhongsheng Pharmaceutical Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Humanigen Inc
  • Hydra Biosciences Inc
  • iBio Inc
  • iCo Therapeutics Inc
  • Idiopathic Pulmonary Fibrosis
  • Idorsia Pharmaceutical Ltd
  • InKemia IUCT Group SA
  • InMed Pharmaceuticals Inc
  • Insmed Inc
  • Inspyr Therapeutics Inc
  • Inventiva
  • Isarna Therapeutics GmbH
  • JHL Biotech Inc
  • Johnson & Johnson
  • Kadmon Corp LLC
  • Knopp Biosciences LLC
  • Kyorin Pharmaceutical Co Ltd
  • Laboratorios LETI SL
  • Lead Discovery Center GmbH
  • LG Chem Ltd
  • LifeMax Laboratories Inc
  • Longevity Biotech Inc
  • Lung Therapeutics Inc
  • Merck & Co Inc
  • Mereo Biopharma Group Plc
  • Meridigen Biotech Co Ltd
  • Miragen Therapeutics Inc
  • Mission Therapeutics Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Moerae Matrix Inc
  • Mycenax Biotech Inc
  • NAL Pharmaceuticals Ltd
  • NeoPharm Co Ltd
  • Novo Nordisk AS
  • Nuevolution AB
  • Nuformix Plc
  • Octapharma AG
  • OliX Pharmaceuticals Inc
  • Omeros Corp
  • OncBioMune Pharmaceuticals Inc
  • Ono Pharmaceutical Co Ltd
  • Onspira Therapeutics Inc
  • Orbis Biosciences Inc
  • Oxagen Ltd
  • Paradigm Biopharmaceuticals Ltd
  • Paragen Bio Pty Ltd
  • PharmaLundensis AB
  • Pieris Pharmaceuticals Inc
  • Pliant Therapeutics Inc
  • Progenra Inc
  • Prommune Inc
  • Pulmagen Therapeutics LLP
  • Pulmokine Inc
  • Pulmotect Inc
  • Quark Pharmaceuticals Inc
  • Qurient Co Ltd
  • Redx Pharma Plc
  • Reliance Life Sciences Pvt Ltd
  • Resolys Bio Inc
  • Revalesio Corp
  • ReveraGen BioPharma Inc
  • Reviva Pharmaceuticals Inc
  • rEVO Biologics Inc
  • Rhizen Pharmaceuticals SA
  • Sam-A Pharm Co Ltd
  • Samumed LLC
  • SATT North SAS
  • Shionogi & Co Ltd
  • Sorrento Therapeutics Inc
  • Swecure AB
  • Synairgen Plc
  • Synermore Biologics Co Ltd
  • Synovo GmbH
  • Syntrix Biosystems Inc
  • Taiho Pharmaceutical Co Ltd
  • TaiwanJ Pharmaceuticals Co Ltd
  • Telocyte LLC
  • Teva Pharmaceutical Industries Ltd
  • The Geneva Biotech Center SA
  • United BioPharma Inc
  • Unizyme Laboratories AS
  • Vascular BioSciences
  • Vectura Group Plc
  • Vicore Pharma AB
  • WhanIn Pharmaceutical Co Ltd
  • Xencor Inc
  • X-Rx Inc
  • Yuhan Corp
  • Yungjin Pharm Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll